Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Capital Expenditures (2018 - 2025)

TransMedics has reported Capital Expenditures over the past 8 years, most recently at -$35000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at -$35000.0 for Q4 2025, down 100.26% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (down 98.65% YoY), and the annual figure for FY2025 was $1.8 million, down 98.65%.
  • Capital Expenditures for Q4 2025 was -$35000.0 at TransMedics, down from $548000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for TMDX hit a ceiling of $114.6 million in Q3 2024 and a floor of -$107.6 million in Q4 2023.
  • Median Capital Expenditures over the past 5 years was $400500.0 (2021), compared with a mean of $6.9 million.
  • Biggest five-year swings in Capital Expenditures: crashed 12350.81% in 2023 and later soared 4665.05% in 2024.
  • TransMedics' Capital Expenditures stood at $3.2 million in 2021, then tumbled by 127.2% to -$864000.0 in 2022, then crashed by 12350.81% to -$107.6 million in 2023, then skyrocketed by 112.65% to $13.6 million in 2024, then tumbled by 100.26% to -$35000.0 in 2025.
  • The last three reported values for Capital Expenditures were -$35000.0 (Q4 2025), $548000.0 (Q3 2025), and $104000.0 (Q2 2025) per Business Quant data.